Mesenchymal stem cells as a potential therapeutic tool to cure cognitive impairment caused by neuroinflammation

doi:10.4252/wjsc.v13.i8.1072

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5246)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

321

WORD

160

HTML

2624

Figures (1-1)

248

Tables (1-1)

259

Sum=3612

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

450

Download

1184

Sum=1634

Aug 26, 2021 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2021; 13(8): 1072-1083
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1072

Mesenchymal stem cells as a potential therapeutic tool to cure cognitive impairment caused by neuroinflammation

Maryna Skok

Maryna Skok, Department of Molecular Immunology, Palladin Institute of Biochemistry NAS of Ukraine, Kyiv 01054, Ukraine

Author contributions: Skok M conceptualized the study and wrote and revised the manuscript.

Conflict-of-interest statement: There is no conflict of interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Maryna Skok, DSc, Academic Fellow, Professor, Senior Researcher, Department of Molecular Immunology, Palladin Institute of Biochemistry NAS of Ukraine, 9 Leontovicha str., Kyiv 01054, Ukraine. skok@biochem.kiev.ua

Received: February 24, 2021
Peer-review started: February 24, 2021
First decision: April 20, 2021
Revised: April 28, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: August 26, 2021
Processing time: 176 Days and 16.7 Hours

Core Tip

Core Tip: Mesenchymal stem cells (MSCs) have a significant therapeutic potential in treating neuroinflammation-related cognitive disfunctions including age-related neurodegenerative diseases. The review summarizes recent data concerning optimization of MSC use for therapeutic purposes with the emphasis on the achievements of the last 2 years. Specific attention is paid to extracellular vesicles secreted by MSCs and to the role of α7 nicotinic acetylcholine receptors. The main conclusion is that therapeutic application of MSCs should include measures to facilitate their homing to the brain, support the survival in the brain microenvironment and stimulate the production of neurotrophic and anti-inflammatory factors.